4-O-[2-O-[2-(甲基氨基)-2-脱氧-alpha-L-吡喃葡萄糖基]-3,5-二脱氧-3-羟基甲基-alpha-L-阿拉伯呋喃糖基]-N,N'-二(氨基亚胺甲基)-D-链霉胺 | 26086-49-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-O-[2-O-[2-(甲基氨基)-2-脱氧-alpha-L-吡喃葡萄糖基]-3,5-二脱氧-3-羟基甲基-alpha-L-阿拉伯呋喃糖基]-N,N'-二(氨基亚胺甲基)-D-链霉胺
• 英文名称: 4-O-[2-O-(2-deoxy-2-methylamino-α-L-glucopyranosyl)-5-deoxy-3-C-formyl-α-L-lyxofuranosyl]-NN'diamidino-D-streptamine
• 英文别名: dihydrodeoxystreptomycin；streptomycin；(1R)-N,N'-dicarbamimidoyl-O⁴-[3-hydroxymethyl-O²-(2-methylamino-2-deoxy-α-L-glucopyranosyl)-α-L-arabino-3,5-dideoxy-pentofuranosyl]-streptamine；(1R)-N,N'-Dicarbamimidoyl-O⁴-[3-hydroxymethyl-O²-(2-methylamino-2-desoxy-α-L-glucopyranosyl)-α-L-arabino-3,5-didesoxy-pentofuranosyl]-streptamin；deoxydihydrostreptomycin；2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2S,3R,4S,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
• CAS: 26086-49-7
• 化学式: C₂₁H₄₁N₇O₁₁
• 分子量: 567.597
• InChiKey: RUQATQQNXCPTLL-PQMJGINDSA-N

物化性质

• 熔点：
  190-195 °C
• 比旋光度：
  D20 -102.5° (water)
• 沸点：
  835.2±75.0 °C(Predicted)
• 密度：
  1.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -7.1
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  319
• 氢给体数：
  12
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 aluminium amalgam 、 硫酸 作用下， 生成 4-O-[2-O-[2-(甲基氨基)-2-脱氧-alpha-L-吡喃葡萄糖基]-3,5-二脱氧-3-羟基甲基-alpha-L-阿拉伯呋喃糖基]-N,N'-二(氨基亚胺甲基)-D-链霉胺
  参考文献：
  名称：

  Ikeda et al., Proceedings of the Japan Academy, 1956, vol. 32, p. 48,51

  摘要：

  DOI：

文献信息

• Prodrugs containing novel bio-cleavable linkers
  申请人：Satyam Apparao

  公开号：US20060046967A1

  公开（公告）日：2006-03-02

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了公式(I)的化合物或其药用可接受的盐。本发明还提供了包含一个或多个公式I的化合物或其中间体以及一个或多个药用可接受的载体、车辆或稀释剂的药物组合物。本发明进一步提供了包括制备方法和使用方法在内的前药，包括释放一氧化氮的前药、双前药和相互前药，由公式I的化合物组成。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• [EN] 2-METHYLTHIOPYRROLIDINES AND THEIR USE FOR MODULATING BACTERIAL QUORUM SENSING<br/>[FR] 2-MÉTHYLTHIOPYRROLIDINES ET LEUR UTILISATION POUR MODULER LA DÉTECTION DU QUORUM BACTÉRIEN
  申请人：FLORIDA INT UNIV BOARD TRUSTEES

  公开号：WO2012174511A1

  公开（公告）日：2012-12-20

  Compounds of Formula (I) are disclosed herein and their use in inhibiting quorum sensing in bacteria.

  本文披露了化学式（I）的化合物及其在抑制细菌中的群体感应中的应用。
• [EN] ANTIBODY-DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：SPIREA LTD

  公开号：WO2021240155A1

  公开（公告）日：2021-12-02

  The present invention relates to antibody-drug conjugates comprising (i) an antibody or antigen-binding fragment thereof, (ii) a polymer comprising a particular repeat unit comprising an amino acid derivative, which is covalently bound to one or more biologically active moieties, such as small molecule drugs, optionally via a linker, and (iii) a polymer-antibody linker moiety which is covalently bound to both the polymer and the antibody or antigen-binding fragment thereof. Additionally, the present invention relates to pharmaceutical compositions comprising the antibody-drug conjugates and to use of the antibody-drug conjugates in medicine.

  本发明涉及抗体-药物偶联物，包括（i）抗体或其抗原结合片段，（ii）聚合物，其中包括一个特定重复单元，该单元包括氨基酸衍生物，与一个或多个生物活性基团如小分子药物共价结合，可选地通过连接剂连接，以及（iii）聚合物-抗体连接基团，它们与聚合物和抗体或其抗原结合片段均共价结合。此外，本发明涉及包括抗体-药物偶联物的药物组合物以及在医学上使用抗体-药物偶联物。
• Nitrate salts of antimicrobial agents
  申请人：——

  公开号：US20030105066A1

  公开（公告）日：2003-06-05

  Nitrate salts of antimicrobial agents for the preparation of antimicrobial medicaments, specifically antiviral, antifungal and antibacterial medicaments.

  抗菌药物的硝酸盐，用于制备抗菌药物，特别是抗病毒、抗真菌和抗细菌药物。